Receptor tyrosine-protein kinase erbB-3

BE0009917ProteinHumansERBB3

Tyrosine kinase receptor that, despite substitutions of key catalytic residues in the kinase domain, retains residual catalytic activity enabling autophosphorylation (PubMed:9148746, PubMed:20351256). It is acted on by 15 drugs in DrugBank.

Gene name
ERBB3
UniProtKB entry
P21860Swiss-Prot
Cellular location
Cell membrane
Residues / weight
1,342 residues · 148,097 Da
Also known as
2.7.10.1 · HER3 · Proto-oncogene-like protein c-ErbB-3 · Tyrosine kinase-type cell surface receptor HER3

Resolves to

Protein
UniProtP21860UniProt nameERBB3_HUMAN
Gene
HGNCHGNC:3431NCBI Gene2065GeneCardsERBB3
Pharmacology
IUPHAR/GtoPdb1798KEGGhsa:2065
Structure
PDB1M6BPDB2L9UPDB3KEX
Drugs

What you can answer from here — as of April 22, 2020

15DrugsApproved to experimental, with action, bond type and pharmacological action
Sign in
15Clinical trialsTrials of drugs acting on it, by phase and status
Sign in
33GO termsFunction, process and component, as structured annotations
Sign in
4Pfam domainsDomain architecture mapped to Pfam families and clans
Sign in
57+ReferencesStructured and connected to the statements they support
Sign in

Which approved drugs act on Receptor tyrosine-protein kinase erbB-3, how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In